These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24746990)

  • 1. Pneumococcal vaccination in Europe: schedule adherence.
    Gervaix A; Ansaldi F; Brito-Avô A; Azzari C; Knuf M; Martinón-Torres F; Tuerlinckx D; Tin Htar MT; Syrogiannopoulos GA
    Clin Ther; 2014 May; 36(5):802-12.e1. PubMed ID: 24746990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to pneumococcal conjugate vaccination schedule and uptake rate as compared to the established diphtheria-tetanus-acellular pertussis vaccination in Cyprus.
    Hadjipanayis A; Efstathiou E; Michaelidou K; Papaevangelou V
    Vaccine; 2018 Sep; 36(38):5685-5691. PubMed ID: 30115523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine.
    Pichichero ME; Bernstein H; Blatter MM; Schuerman L; Cheuvart B; Holmes SJ;
    J Pediatr; 2007 Jul; 151(1):43-9, 49.e1-2. PubMed ID: 17586189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in infants.
    Knuf M; Pankow-Culot H; Grunert D; Rapp M; Panzer F; Köllges R; Fanic A; Habib A; Borys D; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2012 Jan; 31(1):e31-6. PubMed ID: 21909049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
    Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
    Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A current and historical perspective on disparities in US childhood pneumococcal conjugate vaccine adherence and in rates of invasive pneumococcal disease: Considerations for the routinely-recommended, pediatric PCV dosing schedule in the United States.
    McLaughlin JM; Utt EA; Hill NM; Welch VL; Power E; Sylvester GC
    Hum Vaccin Immunother; 2016; 12(1):206-12. PubMed ID: 26376039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components.
    Dagan R; Goldblatt D; Maleckar JR; Yaïch M; Eskola J
    Infect Immun; 2004 Sep; 72(9):5383-91. PubMed ID: 15322036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a minimum interval immunization schedule for diphtheria and tetanus toxoids and acellular pertussis vaccination during a pertussis outbreak.
    Bronson-Lowe D; Anderson SM
    Arch Pediatr Adolesc Med; 2009 May; 163(5):417-21. PubMed ID: 19414686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity.
    Deloria Knoll M; Park DE; Johnson TS; Chandir S; Nonyane BA; Conklin L; Fleming-Dutra KE; Loo JD; Goldblatt D; Whitney CG; O'Brien KL
    Pediatr Infect Dis J; 2014 Jan; 33 Suppl 2(Suppl 2 Optimum Dosing of Pneumococcal Conjugate Vaccine For Infants 0 A Landscape Analysis of Evidence Supportin g Different Schedules):S119-29. PubMed ID: 24336054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
    Vestrheim DF; Løvoll O; Aaberge IS; Caugant DA; Høiby EA; Bakke H; Bergsaker MR
    Vaccine; 2008 Jun; 26(26):3277-81. PubMed ID: 18456376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parental knowledge, attitudes and perception of pneumococcal disease and pneumococcal conjugate vaccines in Singapore: a questionnaire-based assessment.
    How CH; Phua See Chun P; Shafi F; Jakes RW
    BMC Public Health; 2016 Sep; 16(1):923. PubMed ID: 27590503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.
    Rose M; Zielen S
    Expert Rev Vaccines; 2009 Oct; 8(10):1351-64. PubMed ID: 19803758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: translating research into policy.
    Madhi SA; Cohen C; von Gottberg A
    Vaccine; 2012 Sep; 30 Suppl 3():C21-7. PubMed ID: 22939016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine.
    Gimenez-Sanchez F; Kieninger DM; Kueper K; Martinon-Torres F; Bernaola E; Diez-Domingo J; Steul K; Juergens C; Gurtman A; Giardina P; Liang JZ; Gruber WC; Emini EA; Scott DA;
    Vaccine; 2011 Aug; 29(35):6042-8. PubMed ID: 21704105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
    Tregnaghi M; Zambrano B; Santos-Lima E
    Pediatr Infect Dis J; 2012 Jan; 31(1):e24-30. PubMed ID: 22157567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine update: the latest from ACIP.
    Campos-Outcalt D
    J Fam Pract; 2013 Mar; 62(3):137-44. PubMed ID: 23520584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine co-administered with routine vaccine combinations.
    Adam D; Fehnle K
    Vaccine; 2008 Nov; 26(47):5944-51. PubMed ID: 18801402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial.
    Dagan R; Givon-Lavi N; Porat N; Greenberg D
    Vaccine; 2012 Jul; 30(34):5132-40. PubMed ID: 22683519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).
    Johns TL; Hutter GE
    Ann Pharmacother; 2010 Mar; 44(3):515-23. PubMed ID: 20197476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.